Phase 3 Readout
BIIB: Phase 3 Topline: A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants Wit
July 30, 2026 · nusinersen. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 30, 2026
- Company
- BIOGEN INC. (BIIB)
- Drug
- nusinersen
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants Wit
- Company
- BIOGEN INC. (BIIB)
- Drug
- nusinersen
- Indication
- Muscular Atrophy, Spinal